ARGX-118
Autoimmune diseases
Phase 1Active
Key Facts
About Argenx
argenx is a Dutch-American biotechnology company focused on developing innovative antibody therapies for patients suffering from severe autoimmune diseases and cancer. Founded in 2008, the company has successfully commercialized VYVGART® (efgartigimod) for myasthenia gravis and is advancing multiple programs leveraging its proprietary SIMPLE Antibody™ platform. With operations in the Netherlands, Belgium, and the United States, argenx has established itself as a leader in FcRn antagonist therapies and immunology drug development.
View full company profileOther Autoimmune diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Inflammation & Immunology Programs | Pfizer | Phase 2/3 |
| Adalimumab biosimilar (IBI303) | Innovent Biologics | Approved |
| Hulio (Adalimumab) | Biocon | Approved |
| Undisclosed ImmTAAI candidates | Immunocore | Preclinical |
| BHV-1100 (IgG degrader) | Biohaven | Preclinical |
| Bispecifics | Shattuck Labs | IND-Enabling |
| Preclinical Pipeline | Autolus Therapeutics | Pre-clinical |
| FT839 | Fate Therapeutics | Phase 1 |
| IMP761 | Immutep | Phase 1 (planned) |